Compare · BEAT vs DXCM
BEAT vs DXCM
Side-by-side comparison of Heartbeam Inc. (BEAT) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BEAT and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 1187.1x BEAT ($28.3M).
- Over the past year, BEAT is down 58.3% and DXCM is up 16.3% - DXCM leads by 74.5 points.
- DXCM has been more active in the news (9 items in the past 4 weeks vs 6 for BEAT).
- DXCM has more recent analyst coverage (25 ratings vs 9 for BEAT).
- Company
- Heartbeam Inc.
- DexCom Inc.
- Price
- $0.48-2.81%
- $88.53-0.71%
- Market cap
- $28.3M
- $33.65B
- 1M return
- -9.28%
- +18.25%
- 1Y return
- -58.27%
- +16.25%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2005
- News (4w)
- 6
- 9
- Recent ratings
- 9
- 25
Heartbeam Inc.
HeartBeam, Inc., a medical technology company, primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease. It focuses on providing diagnostic data to help physicians with care management of patients with cardiovascular disease. The company is developing its telehealth product that comprises a credit card sized electrocardiograms machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is based in Santa Clara, California.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest BEAT
- Heartbeam Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by Heartbeam Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Heartbeam Inc.
- SEC Form 10-Q filed by Heartbeam Inc.
- HeartBeam Reports Second Quarter 2026 Results
- Heartbeam Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time
- Chief Technology Officer Persen Kenneth Harry was granted 105,740 shares, increasing direct ownership by 31% to 448,290 units (SEC Form 4)
- CFO Cruickshank Tim was granted 167,760 shares, increasing direct ownership by 232% to 239,990 units (SEC Form 4)
- President Vajdic Branislav was granted 3,060,870 shares, increasing direct ownership by 336% to 3,970,784 units (SEC Form 4)
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.